Search results for: 'CDMO industry analysis'

CDMOs are third-party vendors that offer outsourced development and manufacturing services for pharmaceutical drugs. In the small molecule manufacturing sector, CDMOs provide expert development and manufacturing services and are now an essential part of the pharmaceutical industry's value chain. The growing incidence of chronic diseases propels t...

Single-cell analysis can diagnose a condition in heterogenous cell population samples by studying genomics, transcriptomics, proteomics, metabolomics, and other cellular interactions in cells. It helps to understand a tumor microenvironment better and develop drugs based on newly uncovered knowledge of various types of tumors. The rich data provide...

By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more compl...

The global small‑molecule CDMO industry is undergoing a structural transformation driven by increasing molecular complexity, patent expiries, cost pressures, and the strategic need to secure resilient pharmaceutical supply chains. Demand is shifting beyond high‑volume commodity generics toward specialized development and manufacturing capabilities ...

The Sri Lankan government’s commitment to the healthcare and education sectors is commendable. However, the demographic and epidemiological transformation is urging for reforming the primary healthcare delivery model of the country. Non-communicable diseases are on the rise and account for 85% of deaths in the country. The quality of healthcare ser...

This Frost Radar™ analyzes the competitive landscape of the antibody-drug conjugate (ADC) contract development and manufacturing organization (CDMO) market. Companies provide the foundational manufacturing and development services for what has become one of the most dynamic and valuable therapeutic modalities in oncology. The success of the ADC rev...

India’s aviation sector is among the fastest growing in the world and set to become the third largest globally. The current commercial aircraft fleet size is estimated to grow from about 714 aircraft to 2,000 aircraft within the next decade. This aligns with the government’s plans to build 220 new airports and add 1,000 new routes by 2026. The risi...

Natural resource scarcity, the harmful environmental impacts of emissions, and discarded materials in landfills and water bodies are pressing global challenges. The lighting industry significantly contributes to eWaste and pollution, including greenhouse gases and used materials from parts. This challenge warrants adopting circular economy principl...

The bio‑CDMO industry is entering an era of accelerated growth driven by the global shift toward complex biologics, including monoclonal antibodies, antibody-drug conjugates (ADCs), cell and gene therapies, recombinant proteins, and advanced vaccines. Large molecules are projected to record a 10.3% CAGR between 2025 and 2031, signaling sustained de...